10-K/A: Anteris Technologies Files Amendment to 10-K to Include Omitted Information on Directors, Executive Compensation, and Related Matters

Anteris Technologies files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and related corporate governance matters.

Summary

• Anteris Technologies Global Corp. is filing Amendment No. 1 on Form 10-K/A to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Part III of Form 10-K, which was previously omitted.
• The original filing included a definitive proxy statement on the cover page as a document incorporated by reference, but this has been deleted.
• Items 10, 11, 12, 13, and 14 of Part III of the original filing have been amended and restated in their entirety.
• Currently dated certifications from the CEO and CFO have been added as Exhibits 31.3 and 31.4.
• The amendment does not reflect events occurring after the filing of the original filing, nor does it modify or update the disclosures contained in the original filing.
• The company's Board of Directors oversees the management of the business and affairs of the company.
• The Board has three standing committees: the Audit and Risk Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee.
• The company has adopted Corporate Governance Guidelines and a Code of Business Conduct and Ethics.
• The company has employment agreements with its named executive officers (NEOs).
• The company has adopted the Anteris Technologies Global Corp. Equity Incentive Plan for granting options and other awards to employees and service providers.
• The company has a compensation recovery policy that is compliant with the NASDAQ Listing Rules.
• The company has a written related-party transaction policy that applies to its executive officers, directors, director nominees, holders of more than 5% of any class of its voting securities and any member of the immediate family of, and any entity affiliated with, any of the foregoing persons.
• The company and ATL are party to a deed of cross guarantee dated December 20, 2024.
• On April 18, 2023, the company purchased 30% of the equity capital stock of v2vmedtech, inc.
• The total amount of eligible development contributions and operational contributions paid by the company under the v2v Agreements as of December 31, 2024 was $3.6 million.
• The company has entered into agreements to indemnify its directors and executive officers.
• Fees billed by KPMG for the fiscal year ended December 31, 2024 were $649,610 for audit fees.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, relating to the filing of an amendment. While there are some minor negative aspects (e.g., late filings), the overall tone is neutral to slightly positive due to the inclusion of important corporate governance information.

Positives

• The company has implemented corporate governance guidelines and a code of ethics.
• The company has a compensation recovery (clawback) policy.
• The company has a related-party transaction policy to ensure fair dealings.
• The company provides indemnification agreements for its directors and executive officers.

Negatives

• The company had to file an amendment to its 2024 annual report due to previously omitted information.
• Messrs. Paterson and Seaberg each filed a Form 3 late.

Risks

• The company's operation depends on its information technology systems, which are vulnerable to cyber-based attacks.
• Failure to protect the company's information technology infrastructure and products against cyber-based attacks could materially disrupt operations and harm the business.
• The timing for a first in human trial for v2vmedtech cannot be reasonably determined at this time as it is contingent on successful completion of further stages of R&D, including the design, prototyping and testing, preclinical testing and completion of regulatory submissions.

Future Outlook

The company expects that setting key corporate and individual key performance targets which are aligned to the corporate strategy, will drive the development, performance and position of our company and increased stockholder returns going forward.

Industry Context

The company operates in the biomedical technology and healthcare industry, focusing on medical devices. The amendment provides transparency regarding the company's leadership, compensation practices, and related party transactions, which are important for investors in this sector.

Comparison to Industry Standards

• Executive compensation structures, equity incentive plans, and corporate governance practices are generally in line with industry standards for publicly traded companies in the biomedical technology sector.
• The company's approach to cybersecurity risk management is consistent with industry best practices, including periodic risk assessments, penetration testing, and incident response procedures.

Management Changes

Corporate Governance

Related Party Transactions

• The company purchased 30% of v2vmedtech, inc. and has development and operational agreements with them.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• The amendment provides greater transparency for shareholders regarding the company's governance, executive compensation, and related transactions.
• The company's cybersecurity risk management program aims to protect its operations and data, benefiting customers and other stakeholders.

Next Steps

• The company will continue to execute its business strategy and monitor its risk management processes.
• The company will hold its 2025 Annual Meeting of Stockholders.

Key Dates

Keywords

executive compensation, directors, corporate governance, audit fees, equity incentive plan, related party transactions, cybersecurity, v2vmedtech, anteris technologies